KESTRA MEDICAL TECHNOLOGIES, LTD.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Umberger Traci S (See Remarks) sold 100,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $27.18 ($27.15–$28.09, $2.72M total) across 2 trades on 2026-10-21 under a Rule 10b5-1 trading plan.
Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.
Piper Sandler reiterated an Overweight rating and $30 price target for Kestra Medical (KMTS), citing its patent portfolio and revenue growth. The stock has risen 38% in six months, with a market cap of $1.63B. Kestra reported Q1 2027 revenue of $31M, up 60% YoY, but a larger-than-expected loss of $0.75 per share. The company raised its full-year revenue guidance to $141M.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning KMTS (KESTRA MEDICAL TECHNOLOGIES, LTD.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent KMTS coverage spans earnings, insider activity and market movers.
In the last 30 days, KMTS insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($3.3M). The most active reporter was Webster Brian Daniel, See Remarks, with 2 filings. 80% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may create modest selling pressure on KMTS.
Positive analyst coverage is likely to lift the stock as investors price in the higher target.
No new catalyst; price impact unlikely.
No new catalyst; price move already reflected.
Revenue guidance raise may support short‑term upside; operating loss remains large, risk of cash burn.
AlphAI scores every news story that mentions KMTS with an AI model for sentiment and relevance, and aggregates insider trades from KESTRA MEDICAL TECHNOLOGIES, LTD.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Umberger Traci S (See Remarks) sold 100,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $27.18 ($27.15–$28.09, $2.72M total) across 2 trades on 2026-10-21 under a Rule 10b5-1 trading plan.
1 min readKestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.
2 min readPiper Sandler reiterated an Overweight rating and $30 price target for Kestra Medical (KMTS), citing its patent portfolio and revenue growth. The stock has risen 38% in six months, with a market cap of $1.63B. Kestra reported Q1 2027 revenue of $31M, up 60% YoY, but a larger-than-expected loss of $0.75 per share. The company raised its full-year revenue guidance to $141M.
2 min readKestra Medical Technologies reported Q1 FY2027 revenue of $31.0M, beating estimates by $1.4M, but GAAP EPS loss widened to $0.75. Revenue grew 60% YoY, gross margin expanded to 56.5%, and FY2027 guidance was raised to $141.0M. Net loss increased to $44.1M, and cash burn rose. The stock initially fell but later gained 4.74%.
2 min readKestra Medical Technologies (KMTS) reported a 60% revenue increase to $31.0M in Q1 2027, with gross margin rising to 56.5%. The company raised fiscal 2027 revenue guidance to $141M. Gross profit nearly doubled, but operating losses widened to $37.7M due to higher expenses. The company's cash position decreased slightly, with $244.7M remaining.
2 min readKestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.
3 min readKestra Medical Technologies reported Q1 2027 revenue of $30.97M, up 60% YoY, but a net loss of $(44.09)M. Diluted EPS was $(0.75). Growth was driven by increased use of its ASSURE® wearable cardiac defibrillator, with revenue primarily from Medicare, Medicaid, and private payors. The company expanded sales and marketing and improved operational efficiency.
1 min readKESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported
2 min readHanley Conor sold 5,694 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $25.25 ($0.14M total) on 2026-09-08.
1 min readKESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The Kestra Medical Technologies, Ltd. (the “Company”) 2026 annual general meeting of shareholders (the “2026 Annual Meeting”) was held on September 9, 2026. The total number of the Company’s common shares voted in per
1 min read
